A clinical development plan specific to children is a necessary component of every development plan for a new antiepileptic drug (AED). In the last decade, considerable discussion has occurred in the medical and regulatory communities, resulting in specific pediatric drug development legislation. Ethical issues are a foremost consideration in the design and conduct of studies. The timing of clinical studies differs between adults and children. In general, studies in children will not be performed until efficacy and safety has been demonstrated in adults. Exceptions include development of AEDs for seizure types seen only in children. Formulation preparation and dosing selection are often more challenging in children.
INTRODUCTION
Steady progress has been made in the area of drug development for children in the last decade, spurred by growing interest in both the United States and Europe, as well as legislation passed in the mid-1990s in the United States. In general, this progress has included more trials being performed, resulting in efficacy, safety, and dosing data generated from pediatric patients treated with new antiepileptic drugs (AEDs). Many challenges exist in completing a comprehensive development program in a timely fashion in children. 1 Issues such as the timing of pediatric trials relative to trials in adults, the need for additional toxicology studies, and the development of one or more suitable formulations for children need to be addressed. There is clear recognition that when a medication is likely to be used in children it is imperative that appropriate studies be performed in this patient population. This principle has been articulated by regulatory authorities in Guidance ICH E 11, the general principles of which are summarized here (TABLE 1) . This guidance characterizes the scope of the work and the special considerations unique to clinical development for children in general. 2 Although pediatric clinical development will vary for each new AED compound under study, some general principles can be elaborated.
Regulatory background
The regulatory environment for AED drug development has changed a great deal over the past decade, and some of the greatest changes have been seen in pediatric drug development. After initial legislation, the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were passed in 2002 and 2003, respectively. 3, 4 Similar legislation is under development in the European Union. PREA legislates that AEDs must be studied in children. PREA also defines the components necessary for a development program in children. BPCA offers an incentive to perform pediatric studies defined in a written request by granting the compound 6 months exclusivity. The BPCA will sunset in 2007.
Ethical issues
Although continued unmet medical need exists for the study of AEDs in children, ethical considerations dictate certain aspects of trial design and timing of trials in children relative to adults. Children must be protected as research participants. Studies in children must be designed with clearly defined and articulated risks and benefits. Standards are in place in order to evaluate the risks and benefits to the pediatric patients being studied, as well as to the population of children as a whole. 5 These must then be included in the discussion with children and their families when informed consent is obtained-before children are entered into trials.
A workshop on AED drug trials in children was held in 1990 and called for pharmacokinetic (PK) studies to be initiated immediately after PK studies in adults, early in the clinical development process. 6 It is highly questionable to expose pediatric patients to the risk and discomfort associated with PK studies prior to ascertaining proof of efficacy in adults. Many drugs introduced into initial PK studies in adults do not ultimately make it through the development process. If these drugs are indeed abandoned in later phases of development based on lack of efficacy, or unacceptable side effects, children enrolled in such early PK studies would be exposed to new chemical entities with no benefit to them, nor to society as a whole.
Timing issues
Pediatric studies of AEDs in seizure types seen in both adults and children should not, in general, be initiated with a new chemical entity prior to the establishment of the adult dose, serum concentration profile, and a commitment to take the compound forward to registration.
Adult PK and in vitro metabolism data are necessary for planning rational pediatric PK studies. Once it is clear that a given PK profile is associated with the desired therapeutic endpoint and an understanding of the safety of the compound has been determined in adults, then one can rationally and safely plan pediatric studies. A logical exception arises for seizure types not seen in adults, such as infantile spasms, in which case drug development may proceed from PK and early safety studies in adults to PK studies in children. At a U.S. National Institutes of Health consensus conference held in 1994, members called for pediatric PK data and pediatric dosing schedules to be made available at the time of approval (TA-BLE 2). 7 The availability of an appropriate formulation for children will also factor into the start of pediatric studies.
FORMULATION AND TOXICOLOGY
Prior to initiation of trials, a single formulation (or possibly several different formulations) must be developed for children of different ages. This is a resourceintensive and time-consuming process. Initial development work for a commercial pediatric dosage formulation takes in general over 1 year to complete. Development teams plan on 1-1.5 years to complete manufacturing of small amounts of supplies for initial stability, initial clinical studies, and prototype refinement. Additional time will be required to complete the development process for commercial manufacturing. Further steps include transfer of the manufacturing process to commercial sites, manufacture of product for remaining clinical studies, and obtaining stability data for regulatory filings. An additional 2 years are needed to complete a stability program, in order to have an acceptable shelf life at the time of registration (12-18 months).
This work, which can be expected to take at least 4 years, must be completed in advance of a pediatric submission. In a resource-constrained environment, the work will often not begin until clear efficacy and safety data are available in adults. Furthermore, there are challenges of bioavailability, and palatability, along with the inherent issues of liquid formulations and the need for small milligram doses and small dosage form sizes. Every clinical trial is supported by nonclinical toxicology studies in animals. Additional work in animals may be necessary to support a pediatric program, particularly if a safety signal is seen in the standard studies. This necessary work may also influence the onset of clinical trials in children.
CLINICAL TRIALS

Dose selection
Dose selection can be achieved by modeling PK characteristics associated with optimum efficacy and safety in adults, with efficacy extrapolation to children. This provides an efficient approach to minimizing the number of children who need to be studied. Studies in children are in patients, not in normal volunteers. They tend to be studies of fewer patients, using sparse blood sampling techniques, and thus are not as elegant as adult studies. Population PK sampling has been used successfully in AED development for children. 9 Population PK studies are done in clinical settings and so may reflect the real world better than the studies done in traditional normal volunteers. These approaches will minimize the blood volumes that need to be obtained from each individual child, and, in general, avoid the need to do dose ranging studies.
Patient selection
Somewhat arbitrary age categories have been defined for the pediatric group: neonate (0 -1 month), infant (1 month-2 years), child (2-12 years), and adolescent (12-16 years). 2 Both PK and efficacy trials should be proposed based on relevant information. Pharmacokinetic studies should be based on the application of knowledge of the ontogeny of the clearance pathways of the drug in different ages. Clinical trials in children should be based on the seizure type or epilepsy syndrome under study and should include children of appropriate ages.
Epidemiological data are available to help define the number of children with specific seizure types available for potential entry into a trial. The numbers vary by age, consistent with the onset of specific seizure types and epilepsy syndromes. Overall, 30,000 children can be estimated to be diagnosed with epilepsy annually in the United States. 10 Of these 30,000 children, benign partial epilepsy accounts for 3000 children, or 10%. In a population-based cohort study from Nova Scotia, 83% of children with new-onset partial seizures came under control with the first AED. 11 Approximately 4000 children can be estimated to present with absence seizures and 1500 adolescents present with juvenile myoclonic epilepsy (JME) per year in the United States. 10 These generalized epilepsy syndromes usually present in children of ages 6 years and older. Generalized tonicclonic seizures appear to be rare in infants. In one study of 69 infants less than 2 years of age with chronic seizures, none were found to have video-EEG confirmation of generalized tonic-clonic seizures. 12 Statistics for complete response to therapy for absence epilepsy and JME are reported to range from 80% to 90%. 13 Therefore, for both partial and generalized seizure disorders and epilepsies, only a small number of children will fail initial drug therapy and become medically refractory.
Partial seizures do occur in all pediatric age categories. Generalized epilepsy encompasses several seizure types. Studies of absence seizures would include school-age children, studies of JME would include adolescents, and studies of Lennox-Gastaut syndrome (with various seizures associated) would include infants through adults.
The neonatal patient represents a unique challenge for PK and clinical trials. The neonatal population is not homogeneous, and includes both preterm and term infants. Studies may therefore need to be done in several different patient strata, based on gestational age and weight. The neonatal patient is usually acutely ill, and seizures are often symptomatic and due to an underlying CNS or metabolic insult. 11 Trials in this age group would center on acute intervention.
Trial designs
Trials for patients with refractory epilepsy-partial seizures. Randomized, adjunctive therapy trials are suitable for infants and children with refractory seizures. These studies have been performed and information included in labeling for at least three AEDs (Keppra; UCB, Brussels Belgium; Neurontin; Pfizer, New York, NY; Trileptal; Novartis, East Hanover, NJ) approved since 1994. 14, 15 Historically, in studies of adults, the baseline phase ranges from 8 -12 weeks and the treatment phases have been 8 -12 weeks in duration. Patients have been randomized to drug or placebo (see Schmidt in this issue). An analysis of data from several trials has shown that the baseline phase and treatment phase may be shortened and still allow for an acceptable determination of seizure rates and treatment effect. 16 This is particularly relevant for children, allowing for a shorter overall trial and minimizing the amount of time before active treatment is available for each patient. The treatment phase needs to include time for therapy titration and attainment of steady-state drug concentrations, followed by sufficient quantification of seizure counts to justify chronic therapy.
In infants, a shorter baseline and treatment phase may be used, while still allowing for titration and evaluation at steady state. This allows for a shorter phase in which the patient may be exposed to placebo and a shorter time for evaluation of continuing seizures commensurate with the overall duration of the infant's illness. This shorter duration results in an increase in the number of patients enrolled in the trial who do not fulfill the requisite seizure frequency or who are entirely seizure free during the baseline phase. 17 Consideration for replacement or other adjustment in sample-size determination needs to account for this eventuality.
Justification for the control group therapy is needed and varies with the question posed by the trial. Placebo and dose-controlled studies are acceptable alternatives for determination of efficacy. In studies in children, as in adult studies, seizure counts are designated as the primary outcome variable in determination of efficacy (see Schmidt, in this issue). Children and adolescents (2-16 years) can use diaries, much like adults. Accurately classifying seizures in pediatric patients or subjects can be more difficult with younger children than with older children and adolescents. 18 Initial EEG diagnosis and seizure ascertainment may be necessary to accurately quantify seizures during the trial. Seizures in infants are difficult to classify and count clinically; accurate seizure classification and quantification can be ascertained by EEG. Video-EEG monitoring has been successfully used in clinical trials with infants.
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Trials for patients with refractory epilepsy-generalized seizures. Patients with Lennox-Gastaut syndrome and drop attacks have been successfully studied in randomized, placebo-controlled trials, with baseline phases ranging from 4 to 12 weeks and treatment phases from 11 to 16 weeks. Most trials have enrolled both children and adults in the same study. Outcome measures have included counts of drop attacks, EEG monitoring for seizures, and EEG changes. 19, 20 Medically refractory primary generalized tonic-clonic (PGTC) seizures have also been studied in at least one randomized, placebocontrolled trial with an 8-week baseline phase and a 12-week treatment phase.
21
Trials for patients with new-onset epilepsy. Ideally, trials in newly diagnosed patients would be performed as monotherapy. A prerandomization phase is necessary to ensure the diagnosis. The length of the treatment phase needs to be consistent with the likelihood of seizure recurrence, longer for partial seizures (months, years) and shorter for absence seizures (days, weeks). [22] [23] [24] Ethical concerns have led to the choice of an active or dose-controlled as opposed to a placebo-controlled design. 1, 15, 17 Trials of new-onset monotherapy for partial seizures need a long observation phase due to the infrequent occurrence of seizures. In one monotherapy trial in children with partial seizures, more than half of the patients enrolled had no seizures during the 5-day treatment phase (Trileptal, video-EEG evaluation). 15 This eliminated the ability to detect a treatment effect. The long observation period needed limits the possibility of a placebo-controlled design. A dose-controlled design may be used. An exception to this has been in the case of benign epilepsy syndromes, such as rolandic epilepsy, for which a placebo-controlled trial may be considered. 22 New-onset typical absence seizures have been studied in randomized, placebo-controlled studies of several weeks' duration and responder-enriched, placebo-controlled monotherapy designs. The treatment phase has been limited to a few weeks, for ethical reasons, and EEG monitoring has been used, with activation by hyperventilation in one case. 23, 24 Infantile spasms (IS) are a seizure type unique to infants. Many trials have been performed, but relatively few have been prospective, randomized, or controlled. Endpoints have varied between complete cessation of spasms, resolution of hypsarrythmia, determination of relapse rate, or other outcomes. Small numbers of patients have been included in studies, and choice of control therapy and treatment duration has varied. 25 
Study sites
An optimal study site includes an experienced principal investigator and study site personnel. Access to patients with the seizure type under study is critical. The small patient population necessitates potentially long enrollment duration or a large number of study investigator sites, often in multiple countries. 26 It is much more efficient to have a smaller number of investigators enrolling a larger number of patients. Once an investigator has enrolled a single patient, substantial resources must be dedicated to the ongoing conduct of the trial at that site. Additional complexity is added by the need for video-EEG monitoring and the need for a blinded, central interpretation of EEG data. All of these issues increase the level of difficulty in conducting trials in children.
SPECIAL SAFETY ISSUES IN CHILDREN
Common adverse events as well as long-term safety may differ between adults and children. Therefore, collection of safety data and evaluation in the appropriate pediatric populations is critically important. The ability to collect meaningful data in terms of growth and development as well as behavior and cognitive function is complicated by the patient populations under study and the short duration of the efficacy trials. Longer follow-up may be obtained, but a lack of appropriate information about the natural history of the study group makes interpretation of such data difficult. In approximately half of children diagnosed with epilepsy for which a known cause is identified, the underlying condition is mental retardation or cerebral palsy. 10 Long-term studies should include evaluations of growth and development.
CONCLUSIONS
A wide range of seizure types and epilepsy syndromes present clinically during childhood. The results of pediatric AED development programs have begun to fill in the gaps in our knowledge about efficacy, safety, and appropriate dosing of AEDs. Supported by formulation and toxicology work, the trials designed have been adapted to the special needs of children. In concert with adult trials, trials in refractory seizure types and epilepsy syndromes have the most consistent trial designs and can be expected to continue as part of most pediatric development programs. 16, 27 Adaptations for younger children and infants have included shortening the baseline and treatment phases and counting seizures using video-EEG monitoring. New-onset seizures offer more challenges in trial design from both an ethical and practical perspective.
We still need trials and development programs, particularly for generalized seizures and epilepsy syndromes such as PGTC, JME, and IS. 28 An evolution of trial design may provide for ethical, practical, and interpretable studies but will not overcome the recruitment challenges due to small numbers of children with various seizure types. Thus, multicenter trials will continue to be designed and conducted on a worldwide basis. 26 
